Clinical Trial

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
Protocol Amendment History 1 change
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-21
Trial Details
NCT Number NCT07567781
Lead Sponsor AbbVie
Conditions Healthy Volunteers
Enrollment 12 participants
Start Date 2026-04-30
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-20